Nevirapine toxicity in a cohort of HIV-1–infected pregnant women
| Autor: | Haroldo José de Matos, Esau Joao, Marcos Machado D’Ippolito, Jacqueline A. Menezes, Luisa Andrea T. Salgado, Maria Letícia Santos Cruz, Guilherme Amaral Calvet |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
medicine.medical_specialty Nevirapine Anti-HIV Agents HIV Infections Cohort Studies Pregnancy Internal medicine Humans Medicine Pregnancy Complications Infectious Sida Retrospective Studies Cholestasis biology Reverse-transcriptase inhibitor business.industry virus diseases Obstetrics and Gynecology Retrospective cohort study Odds ratio Hepatitis B biology.organism_classification Hepatitis C CD4 Lymphocyte Count Stevens-Johnson Syndrome Immunology Toxicity Cohort Female business medicine.drug Cohort study |
| Zdroj: | American Journal of Obstetrics and Gynecology. 194:199-202 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/j.ajog.2005.05.015 |
| Popis: | Objective The purpose of this study was to complete an evaluation of nevirapine (NVP) toxicity in a cohort of HIV+ pregnant women. Study design This was a retrospective study of 611 women followed from January 1996 to December 2003. All women who used NVP for >7 days were included. Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP. Results One hundred ninety-seven women were exposed to NVP for >7 days, and toxicity occurred in 11 (5.6%), leading to drug discontinuation in 7 patients. One case of Stevens-Johnson syndrome occurred. No serious liver toxicity occurred except for 1 grade 4 cholestasis. Median CD4 was 344 in women without toxicities and 298 in women with toxicities. HCV was the only significant factor associated to toxicity by logistic regression (odds ratio [OR] 15.61, P = .001). Conclusion NVP toxicities occurred in a very small fraction of patients and were not associated with fatalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect